<DOC>
	<DOCNO>NCT01519713</DOCNO>
	<brief_summary>This study design assess safety immunogenicity single dose Meningococcal ( Groups A , C , Y W-135 ) Polysaccharide Diphtheria Toxoid Conjugate Vaccine ( SP284 ) support registration product Japan . Primary Objective : - To describe seroprotection rate [ % subject serum bactericidal assay use baby rabbit complement ( SBA-BR ) ≥1:128 ] meningococcal antigen ( serogroups A , C , Y W-135 ) follow vaccination SP284 vaccine subject 2 55 year age Secondary Objectives : - To describe safety follow receipt SP284 vaccine subject 2 55 year age - To describe immune response meningococcal antigen ( serogroups A , C , Y W-135 ) follow vaccination SP284 vaccine subject 2 55 year age .</brief_summary>
	<brief_title>Study Single Dose Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine ( SP284 ) Japanese Subjects</brief_title>
	<detailed_description>All participant receive single injection Meningococcal ( Groups A , C , Y W-135 ) Polysaccharide Diphtheria Toxoid Conjugate vaccine Day 0 undergo immunogenicity assessment safety monitor post-vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 55 year day inclusion For subject ≥ 20 year age : Informed consent form sign dated subject . For subject 2 19 year age : Informed consent form sign dated parent ( ) legal representative . Also subject 7 11 year age provide assent subject 12 19 year age provide write assent form . Able attend schedule visit comply trial procedure For woman childbearing potential , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination . Any acute and/or serious disease/illness , opinion investigator , stage might interfere trial conduct completion History meningococcal disease , confirm either clinically , serologically , microbiologically Known systemic hypersensitivity vaccine component , history life threaten reaction vaccine contain substance study vaccine Known suspect congenital current/ previous acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial inclusion Planned participation another clinical trial present trial period Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine within four week precede trial vaccination , except influenza vaccination , may receive least two week study vaccine Planned receipt vaccine trial period Clinical known serological evidence systemic illness include hepatitis B , hepatitis C and/or human immunodeficiency virus ( HIV ) infection Ineligible accord investigator 's clinical judgment Known pregnancy , suspect pregnancy positive ( serum and/or urine ) pregnancy test Currently breast feed child Known thrombocytopenia , contraindicate intramuscular ( IM ) vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate IM vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator Previous vaccination meningococcal disease either trial vaccine another vaccine History GuillainBarré Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>Meningococcal conjugate Vaccine</keyword>
	<keyword>Menactra®</keyword>
</DOC>